BioSpace News Archive

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 11, 2022.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022.

Cutera, Inc. (Nasdaq: CUTR ) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the second quarter after the market close on Thursday, August 4, 2022.

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan’s Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage.

iPreg Incorporation, an award-winning biomedical device manufacturer in the field of reproductive medicine, has developed a new and enhanced solution for infertility.

DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been clearedto treat pain following a Caesarean-section (C-section).

Therapeutic Solutions International reported the successful generation of gene-edited and/or gene-modified regenerative cells possessing mixtures of properties between mesenchymal stem cells and tolerance inducing immune cells.

Denovo Biopharma LLC (“Denovo”), a pioneer in applying precision medicine to the development of innovative therapies, today announced dosing of the first patient in its biomarker-guided global Phase 2b clinical trial (the “ENLIGHTEN” study) to assess the safety and efficacy of DB104 (liafensine) in patients with treatment resistant depression (TRD).

Checkpoint Surgical announced today the launch of the Checkpoint Edge™ Nerve Cutting Kit, extending the breadth of the company’s intraoperative nerve care portfolio.

UBC, a biopharmaceutical leader providing integrated clinical, safety, and commercialization services, announced that it has acquired Examoto, LLC, a Risk Evaluation and Mitigation Strategy company.